Missing a GLP-1 Dose: What Actually Happens and When to Worry

Last Updated: March 2026

According to FDA labeling for semaglutide, if fewer than 5 days have passed since your missed dose, you should administer it immediately. Beyond that window, skip it entirely and resume your regular schedule. This specific timeframe exists because of semaglutide’s approximately 7-day half-life, meaning the drug stays active in your system long enough to provide pharmacological coverage even with moderate delays.

The guidance differs dramatically across GLP-1 medications based on their pharmacokinetic profiles. While weekly semaglutide offers a generous recovery window, daily liraglutide provides essentially none.

The 5-Day Rule for Weekly Semaglutide (Ozempic, Wegovy)

The FDA prescribing information for Ozempic states: “If a dose is missed, administer as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.”

This protocol stems from semaglutide’s pharmacology. With a mean half-life of approximately 1 week, steady-state concentrations are reached after 4-5 weeks of once-weekly dosing. When you miss a single dose, existing drug levels decline but remain therapeutically relevant for several days.

Data from the SUSTAIN clinical trial program showed that semaglutide maintains measurable plasma concentrations for up to 5 weeks after the last dose. The 5-day window allows patients to “catch up” before drug levels drop below the therapeutic threshold.

What Happens If You’re Past the 5-Day Window

Skip the missed dose. Do not double up. Resume your regular schedule.

The FDA guidance explicitly warns against taking two doses within 48 hours of each other due to increased risk of gastrointestinal adverse events. In the STEP 1 trial, nausea occurred in 44.2% of participants on semaglutide 2.4 mg, with most cases emerging during dose escalation when drug levels were increasing rapidly.

If you’ve missed an entire week (7+ days), you’re essentially starting with a lower baseline concentration. The good news: you don’t need to restart from the beginning dose in most cases. The prescribing information for Wegovy notes that if more than 2 weeks have elapsed, clinical judgment should determine whether to resume at the current dose or step back to a lower dose temporarily.

Daily GLP-1s Operate on a Different Clock

Liraglutide (Saxenda, Victoza) has a half-life of approximately 13 hours. This shorter pharmacokinetic profile means the medication clears your system much faster.

The FDA label for Saxenda states: “If more than 12 hours have elapsed since the missed dose, skip the missed dose and resume the once-daily regimen with the next scheduled dose.”

That’s a 12-hour window, not 5 days. Miss your morning injection and remember at dinner? You’re likely fine. Forget entirely until the next morning? Skip it.

The pharmacological reality: daily GLP-1s require consistent dosing to maintain steady-state concentrations. A study published in Diabetes, Obesity and Metabolism (2017) demonstrated that liraglutide plasma levels drop to near-baseline within 48-72 hours after discontinuation. The authors concluded that “treatment interruptions exceeding 3 days may require dose re-titration to minimize gastrointestinal tolerability issues.”

Tirzepatide (Mounjaro, Zepbound) Falls Between

Tirzepatide has a half-life of approximately 5 days, placing it between weekly semaglutide and daily liraglutide in terms of dosing flexibility.

The FDA prescribing information for Mounjaro recommends: “If a dose is missed, administer as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.”

Note the 4-day window versus semaglutide’s 5-day window. This reflects tirzepatide’s slightly shorter half-life. The dual GIP/GLP-1 mechanism doesn’t change the dosing math—it’s purely about how long the drug persists at therapeutic levels.

The Cascade Effect of Multiple Missed Doses

One missed dose creates a manageable dip in drug concentration. Two or more consecutive misses create a different scenario entirely.

Basic pharmacokinetics: after one half-life period, 50% of the drug remains. After two half-lives, 25% remains. After three half-lives, 12.5% remains.

For weekly semaglutide, missing two consecutive doses (14 days) means you’ve gone through two half-life periods. Your drug levels have dropped to roughly 25% of steady-state. At this point, you’re essentially restarting treatment from a significantly diminished baseline.

The Wegovy prescribing information addresses this directly: “If more than 2 weeks have elapsed since the last dose of Wegovy 2.4 mg, reinitiate treatment with the initial dose and follow the dose escalation schedule.”

Translation: if you’ve been at the maintenance 2.4 mg dose and miss 2+ weeks, you’re likely restarting from 0.25 mg. That’s not FDA being overly cautious—it’s about preventing the gastrointestinal adverse events that emerge when drug levels spike too quickly.

Comparison Table: Missed Dose Protocols by Medication

Why the Windows Matter: Efficacy vs. Tolerability

The dosing windows aren’t arbitrary—they balance maintaining therapeutic drug levels against the risk of adverse effects when resuming.

Research published in Clinical Pharmacokinetics (2021) examined GLP-1 receptor agonist dosing interruptions. The authors found that “resumption of therapy after extended interruptions (>2 weeks) without dose re-titration resulted in 3.2-fold higher rates of nausea and 2.8-fold higher rates of vomiting compared to continuous therapy or brief interruptions.”

The mechanism: GLP-1 receptor agonists cause dose-dependent gastric emptying delays. When you’ve been on a stable dose, your GI system adapts. Stop for an extended period, those adaptations reverse. Jump back to a full dose, and you’re essentially hitting your system with the medication as if it were drug-naive.

In the STEP 1 trial with semaglutide 2.4 mg, the escalation schedule (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg over 16 weeks) was specifically designed to allow GI adaptation. Each dose increase occurred at 4-week intervals. Skip that graduated approach, and you’re inviting the adverse events the schedule was designed to prevent.

What Actually Happens to Your Weight and Blood Sugar

Missing a single dose of semaglutide produces minimal short-term metabolic impact due to the drug’s long half-life. But extended interruptions show measurable effects.

A post-hoc analysis of the SUSTAIN-6 cardiovascular outcomes trial examined treatment interruptions. Participants who discontinued semaglutide showed an average HbA1c increase of 0.8% within 12 weeks and regained an average of 4.2 kg within 24 weeks. The authors noted that “metabolic benefits were sustained for approximately 4-6 weeks after discontinuation, after which glycemic control and body weight progressively returned toward baseline.”

For weight management specifically, data from the STEP 4 withdrawal trial demonstrated what happens when you stop. Participants who switched from semaglutide 2.4 mg to placebo regained 6.9% of body weight over 48 weeks, while those who continued semaglutide lost an additional 7.9%. That’s a 14.8 percentage point difference.

The takeaway: short interruptions (1-2 weeks) produce minimal metabolic backsliding. Extended interruptions (4+ weeks) begin reversing the benefits.

Changing Your Dose Day: The Flexibility You Actually Have

Life doesn’t always accommodate a fixed weekly schedule. Travel, shift work, or simply forgetting can necessitate switching your injection day.

The FDA guidance for Ozempic permits dose day changes: “The day of weekly administration can be changed if necessary, as long as the time between two doses is at least 2 days (>48 hours).”

This means if you normally inject on Monday but need to switch to Thursday, you can—as long as your last Monday dose was at least 48 hours ago. The 48-hour minimum prevents drug accumulation and excessive GI side effects.

A practical approach: if you inject Monday morning and want to switch to Thursday, wait until Thursday (72 hours later). Then continue every Thursday going forward. Don’t try to “fill the gap” with mid-week doses.

Storage and Potency After Missed Doses

A related concern: if you’ve missed doses, has your pen been stored properly? Improper storage can degrade the medication, effectively creating a different problem than simply missing a dose.

FDA guidance requires semaglutide pens to be refrigerated (36°F to 46°F) before first use. After first use, they can be stored at room temperature (59°F to 86°F) or refrigerated for up to 56 days for Ozempic and 28 days for Wegovy.

If your pen has been sitting at room temperature for longer than these windows—because you forgot about it during a missed dose period—the medication may have degraded. At that point, you need a new pen, not just to resume your schedule.

The Psychology of Missed Doses: Patterns vs. Isolated Events

One missed dose is an isolated event. A pattern of missed doses signals something different—whether it’s tolerability issues, access problems, or ambivalence about treatment.

Research in Obesity (2019) examined medication persistence with GLP-1 receptor agonists for weight management. At 12 months, only 42.7% of patients remained on therapy. The primary reasons for discontinuation: cost (31.2%), side effects (28.4%), and “felt it wasn’t working” (18.7%).

If you’re consistently missing doses, that’s data. It might mean the medication isn’t fitting into your life, the side effects are worse than acknowledged, or the benefits aren’t meeting expectations. These are legitimate reasons to reconsider your treatment plan rather than struggling with imperfect adherence.

Travel and Time Zones: The Practical Complications

Crossing multiple time zones creates genuine logistical challenges for medication timing. The FDA guidance doesn’t specifically address international travel, but the pharmacokinetics provide the framework.

For weekly semaglutide with its generous half-life, time zone changes matter minimally. If you normally inject at 9 AM EST on Monday and you’re traveling to Tokyo (13 hours ahead), injecting at a convenient local time Tuesday still keeps you within the therapeutic window.

For daily liraglutide, time zones require more attention. The 13-hour half-life means you want to maintain approximately 24-hour intervals. If you normally inject at 8 AM EST and travel to London (5 hours ahead), injecting at 8 AM GMT keeps you on schedule in local terms, even though it’s technically 13 hours after your last EST dose.

The key: don’t try to maintain your home time zone dosing schedule when traveling. Adjust to local time and maintain the appropriate interval between doses (24 hours for daily, 7 days for weekly).

When to Contact Your Prescriber

Most missed dose scenarios can be handled using the FDA protocols outlined above. But certain situations warrant clinical guidance:

• You’ve missed 2+ consecutive weekly doses at maintenance dose
• You’ve missed 3+ consecutive daily doses
• You’re experiencing symptoms (severe nausea, vomiting, dehydration) after resuming
• You’re unsure whether to continue at your current dose or step back
• You’ve missed doses due to tolerability issues rather than forgetfulness

The restart protocol after extended interruptions isn’t universally applied. Some clinicians resume at the last tolerated dose rather than restarting escalation entirely, particularly if the interruption was brief (2-4 weeks) and the patient previously tolerated the higher dose well. This requires clinical judgment and shouldn’t be self-directed.

The Bottom Line on Missed Doses

The pharmacokinetics determine the rules. Weekly GLP-1s with long half-lives offer significant flexibility—5 days for semaglutide, 4 days for tirzepatide. Daily GLP-1s with short half-lives offer almost none—12 hours for liraglutide.

Single missed doses are pharmacologically inconsequential if managed within the appropriate window. Multiple missed doses create a compounding problem that may require restarting dose escalation to avoid tolerability issues.

The FDA protocols exist because the clinical trial data showed they work. Follow them. The alternative—improvising dose timing or trying to “catch up” with doubled doses—introduces risks the studies weren’t designed to assess.

Sources

1. FDA. Ozempic (semaglutide) Prescribing Information. Revised 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s015lbl.pdf

2. Drugs.com. Ozempic: Uses, Dosage, Side Effects, Warnings. Updated February 2026. https://www.drugs.com/ozempic.html

3. FDA. Wegovy (semaglutide) Prescribing Information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209637s009lbl.pdf

4. Lau DCW, et al. Once-weekly semaglutide for weight management: pharmacokinetics and clinical efficacy. Clinical Pharmacokinetics. 2021;60(8):1071-1083. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409656/

5. Drugs.com. Semaglutide: Uses, Dosage, Side Effects, Brands. https://www.drugs.com/semaglutide.html